Press release Nov. 20th 2006

A-Viral’s drug candidate, AV 1101 showed promising results in our initial study on cancer in mice. Our press release of Sept 22nd was issued after 98 days, and the study was terminated at 102 days with no more animals falling ill in this short period, and autopsy of the animals did not change our conclusions stated in our previous press release.

Press release Sept. 22nd 2006

A-Viral’s cancer study on mice has been evaluated at 98 days after onset, and it was decided to end the study by Friday Sept. 22nd. The preliminary results at day 98 were statistically inconclusive, but quite promising.

Press release October 14th 2005

A-Viral has completed its GLP study to establish LD 50 in rats. The conclusion is that at doses more than 100 times what has been used in humans, it was not possible to show any sign of severe toxicity, nor was it possible to reach lethal doses.

Press release July 1st 2005

A-Viral will start a series of animal studies to clarify the relation between liver affection and dose of AV 1101. The studies are planned to start in August, and will follow GLP standards. Thereafter also cancer studies will be carried out.

Press release May 18th 2005

A-Viral has filed patent applications for several promising substances. All substances are new, and they are applied for as molecular patents.

Press release Jan. 5th 2005

A-Viral's study on RA in Amsterdam is stopped, and the available data analyzed. It is clear that the dose used was too high. There is no clear indication in the data for efficacy of the drug against RA.

Press release Oct. 11th 2004

A-Virals study on RA in Amsterdam is suspended because it seems likely that the study drug at a dose of 200 mg daily in combination with another drug can give serious side effects.

Press release Sep. 7th 2004

MD Gert-Jan Wolbink, who is in charge of the RA-study at the Dutch National Centre for Rheumatoid Diseases, reports that recruitment of patients is going faster, and 15 out of 30 patients have been enrolled.

Press release Jun. 28nd 2004

A-Viral's phase 2 study on RA is progressing well, and has attracted attention from several of the world's major pharmaceutical companies, who has asked for meetings to evaluate our technology. Also biotech investors ask for presentations.